Corrigendum

Corrigendum to “Risk Factors for Fracture in Diabetes: The Canadian Multicentre Osteoporosis Study”

Lisa-Ann Fraser,1,2 Alexandra Papaioannou,3,4 Jonathan D. Adachi,4 Jinhui Ma,3 and Lehana Thabane3,5

1Department of Medicine, University of Western Ontario, 339 Windermere Road, London, ON, Canada N6A 5A5
2Division of Endocrinology and Metabolism, St. Joseph’s Hospital, 268 Grosvenor Street, London, ON, Canada N6A 4V2
3Department of Epidemiology and Biostatistics, McMaster University, 1280 Main Street West, Hamilton, ON, Canada L8S 4K1
4Department of Medicine, McMaster University, 1280 Main Street West, Hamilton, ON, Canada L8S 4K1
5Centre for Evaluation of Medicines, St. Joseph’s Healthcare, 50 Charlton Avenue East, Hamilton, ON, Canada L8N 4A6

Correspondence should be addressed to Alexandra Papaioannou; papaioannou@hhsc.ca

Received 6 June 2017; Accepted 8 June 2017; Published 12 July 2017

Copyright © 2017 Lisa-Ann Fraser et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Risk Factors for Fracture in Diabetes: The Canadian Multicentre Osteoporosis Study” [1], there was an error regarding the FRAX® tool, which should be clarified as follows.

The article notes: “The WHO fracture risk assessment tool (FRAX), a commonly used fracture prediction tool, has been found to underestimate fracture risk in the diabetic population [10].” However, the World Health Organization (WHO) did not develop, test, or endorse the FRAX tool or its recommendations [2]. The metabolic bone disease unit at the University of Sheffield that developed FRAX was a WHO Collaborating Centre from 1991 to 2010, but treatment guidelines must undergo a formal process before they can be endorsed by the WHO.

References

